Leukemia Research
Volume 30, Issue 9 , Pages 1077-1078 , September 2006

Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?

Received 20 March 2006

References 

  1. Klein I, Sarkadi B, Vavadi A. An inventory of the human ABC proteins. Biochim Biophys Acta. 1999;1461:237–262
  2. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 1985;316:817–819
  3. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem. 2003;278:8294–8299
  4. Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol. 2004;11(10):918–926
  5. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997;89:3323–3329
  6. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood. 2004;104(7):1940–1951
  7. Galski H, Sivan H, Lazarovici P, Nagler A. In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies. Leuk Res. 2006;30:1150–1157

PII: S0145-2126(06)00129-9

doi: 10.1016/j.leukres.2006.03.014

Leukemia Research
Volume 30, Issue 9 , Pages 1077-1078 , September 2006

Article Tools